{
    "title": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Creating Transparency to Have Drug \nRebates Unlocked (C-THRU) Act of 2017''.\n\nSEC. 2. PUBLIC DISCLOSURE OF DRUG DISCOUNTS.\n\n    (a) In General.--Section 1150A of the Social Security Act (42 \nU.S.C. 1320b-23) is amended--\n            (1) in subsection (c), in the matter preceding paragraph \n        (1), by striking ``this section'' and inserting ``subsection \n        (b)(1)''; and\n            (2) by adding at the end the following new subsection:\n    ``(e) Public Availability of Certain Information.--In order to \nallow patients and employers to compare PBMs' ability to negotiate \nrebates, discounts, and price concessions and the amount of such \nrebates, discounts, and price concessions that are passed through to \nplan sponsors, beginning January 1, 2018, the Secretary shall make \navailable on the Internet website of the Department of Health and Human \nServices the information provided to the Secretary under paragraphs (2) \nand (3) of subsection (b) with respect to each PBM. The Secretary shall \nensure that such information is displayed in a manner that prevents the \ndisclosure of information on rebates, discounts, and price concessions \nwith respect to an individual drug or an individual plan.''.\n    (b) Effective Date.--The amendments made by subsection (a) shall \ntake effect on January 1, 2018.\n\nSEC. 3. MINIMUM DRUG DISCOUNTS REQUIRED TO BE PASSED THROUGH TO THE \n              PLAN SPONSOR.\n\n    (a) In General.--Section 1150A of the Social Security Act (42 \nU.S.C. 1320b-23), as amended by section 2(a)(2), is amended--\n            (1) in the heading, by inserting ``; minimum drug discounts \n        required to be passed through to the plan sponsor'' before the \n        period at the end; and\n            (2) by adding at the end the following new subsection:\n    ``(f) Minimum Drug Discounts Required To Be Passed Through to the \nPlan Sponsor.--\n            ``(1) Requirement.--Beginning January 1, 2020, a PBM that \n        manages prescription drug coverage under a contract with a PDP \n        sponsor or MA organization described in subsection (b)(1) or a \n        qualified health benefits plan described in subsection (b)(2), \n        shall, with respect to the plan sponsor of a health benefits \n        plan, pass through to the plan sponsor a minimum percent (as \n        established by the Secretary) of the aggregate amount of the \n        rebates, discounts, or price concessions that the PBM \n        negotiates that are attributable to patient utilization under \n        the plan.\n            ``(2) Establishment.--The Secretary shall establish the \n        minimum percent described in paragraph (1) in such a manner as \n        will ensure that patients receive the maximum benefit of \n        rebates, discounts, or price concessions while taking into \n        account the costs of negotiating such rebates, discounts, and \n        price concessions.\n            ``(3) Enforcement.--A PDP sponsor of a prescription drug \n        plan or an MA organization offering an MA-PD plan under part D \n        of title XVIII may not contract with a PBM that is not in \n        compliance with the requirement under paragraph (1).''.\n    (b) Effective Date.--The amendments made by subsection (a) shall \ntake effect on January 1, 2020.\n\nSEC. 4. PART D NEGOTIATED PRICES REQUIRED TO TAKE INTO ACCOUNT ALL \n              PRICE CONCESSIONS AT THE POINT-OF-SALE.\n\n    (a) In General.--Section 1860D-2(d)(1)(B) of the Social Security \nAct (42 U.S.C. 1395w-102(d)(1)(B)) is amended--\n            (1) by striking ``prices.--For purposes'' and inserting \n        ``prices.--\n                            ``(i) In general.--For purposes''; and\n            (2) by adding at the end the following new clause:\n                            ``(ii) Negotiated prices at point-of-\n                        sale.--\n                                    ``(I) In general.--Negotiated \n                                prices for covered part D drugs \n                                described in clause (i), including all \n                                price negotiated concessions, shall be \n                                provided at the point-of-sale of the \n                                covered part D drug. If the negotiated \n                                price, including all negotiated price \n                                concessions, is not possible to \n                                calculate at the point-of-sale, an \n                                approximate negotiated price (as \n                                established by the Secretary) shall be \n                                used under the prescription drug plan \n                                or MA-PD plan.\n                                    ``(II) Approximate negotiated \n                                price.--In determining an approximate \n                                negotiated price for a covered part D \n                                drug under subclause (I), the Secretary \n                                shall ensure that--\n                                            ``(aa) such price reflects \n                                        the estimated negotiated price \n                                        that is based on the previous \n                                        year's negotiated price \n                                        concessions negotiated under \n                                        the plan for all or similar \n                                        covered part D drugs or is \n                                        based on such other factors as \n                                        the Secretary may determine \n                                        appropriate; and\n                                            ``(bb) the use of such \n                                        price does not prevent the use \n                                        of value-based contracts \n                                        between drug manufacturers, PDP \n                                        sponsors, MA organizations, and \n                                        pharmacies.''.\n    (b) Effective Date.--The amendment made by subsection (a) shall \napply to plan years beginning on or after January 1, 2019."
}